GRAIL's PATHFINDER 2 Study Results From ASCO 2026

Dr. Nima Nabavizadeh shares data from the primary analysis of PATHFINDER 2, the largest interventional multi-cancer early detection (MCED) study in the U.S. Presented at the 2026 ASCO Annual Meeting, these results explore the performance of GRAIL’s Galleri test in population screening. More information: https://bit.ly/4x1wNIz Learn more: https://grail.com https://galleri.com Galleri should be used in addition to healthcare provider recommended screening tests. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. Rx only. See Important Safety Information: http://bit.ly/33m8pFa